Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Developing the ideal inhaled corticosteroid.

Franklin Cerasoli1

  • 1Global Respiratory Medical Affairs, Altana Pharma AG, 210 Park Ave, Florham Park, NJ 07932, USA. frank.cerasoli@altanapharma-us.com

Chest
|July 15, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety of inhaled corticosteroids: room for improvement.

Pulmonary pharmacology & therapeutics·2005
Same author

Pharmacodynamic evaluation of the neutralization of endotoxin by PMX622 in mice.

Antimicrobial agents and chemotherapy·2004
Same journal

Wearable-derived activity and physiological changes following pleural intervention in malignant pleural effusion.

Chest·2026
Same journal

The effect of a two-day stay at high altitude (2500 m) on right ventricular afterload and oxygen delivery in patients with pulmonary vascular disease A randomized controlled crossover trial.

Chest·2026
Same journal

A Comparative Study of Radiation Exposure in Conventional and Robotic Bronchoscopy.

Chest·2026
Same journal

Independent Prognostic Contributions of Anti-Ro52 and Anti-MDA5 in Autoimmune-Associated Interstitial Lung Disease.

Chest·2026
Same journal

Lung aeration and gas exchange in SGA or AGA infants with moderate-severe BPD: secondary analysis of the PATH-BPD study.

Chest·2026
Same journal

Lung Cancer Incidence and Mortality after Negative Low-Dose CT Screening Results.

Chest·2026
See all related articles

New inhaled corticosteroids (ICS) like ciclesonide offer improved safety and efficacy for asthma management. These advancements aim for better lung function and reduced side effects with convenient dosing.

Area of Science:

  • Pulmonology
  • Pharmacology

Background:

  • Inhaled corticosteroids (ICS) are primary asthma treatments, but side effect concerns limit their use.
  • An ideal ICS requires a superior therapeutic ratio for dose escalation without increased adverse events.

Purpose of the Study:

  • To evaluate the pharmacokinetic and clinical profile of the novel ICS, ciclesonide.
  • To assess ciclesonide's potential for improved asthma management and reduced side effects.

Main Methods:

  • Review of ciclesonide's pharmacokinetic properties: high pulmonary deposition, active metabolite conversion, receptor potency, retention, low oral bioavailability, metabolism, and elimination.
  • Analysis of clinical trial data on ciclesonide's efficacy in improving lung function, controlling inflammation, and its safety profile.

Related Experiment Videos

Main Results:

  • Ciclesonide exhibits ideal pharmacokinetic properties for maximizing efficacy and minimizing systemic exposure.
  • Clinical studies show ciclesonide improves lung function, reduces inflammation, and demonstrates a favorable side effect profile compared to other ICS.
  • Ciclesonide is effective as monotherapy for persistent asthma with once-daily dosing.

Conclusions:

  • Ciclesonide represents a promising ICS with an improved therapeutic index.
  • Further long-term studies are needed to confirm benefits in general clinical practice.
  • ICS with enhanced profiles may improve adherence and broaden the applicability of ICS monotherapy.